
Education

Bachelor of Arts in Philosophy; Emory University; Atlanta, Georgia	1987
Doctor of Medicine; Temple University School of Medicine; Philadelphia, Pennsylvania	1993
Internal Medicine Residency; University of Colorado Health Sciences Center Denver Colorado	1993-1996
Cardiology Fellowship; University of Colorado Health Sciences Center Denver, Colorado	1998-2001

Board Certification

Diplomate, American Board of Internal Medicine	Nov. 1996
Diplomate, American Board of Internal Medicine, Cardiology	Nov. 2001
Fellow, American College of Cardiology (ACC)	May 2003

Honors

Philosophy Honors Society, Emory University	1987
Upjohn Achievement Award in Medical Pharmacology	1992
Alpha Omega Alpha Honor Society: Member Epsilon Chapter, Temple University	1993
Guidant Foundation Award Recipient for outstanding program in Cardiology	2001
Gilbert Blount Cardiology Scholarship Recipient	2001
Colorado Foundation for Medical Care Excellence award, Acute MI	2002
Get with the Guidelines Recognition Award, American Heart Association	2002
Get with the Guidelines Performance Achievement Award, AHA	2003

Publications

1. Batal H, **Krantz MJ**, Mehler PS, Steiner JF. Prescription size and adherence to pharmacologic treatment of hyperlipidemia (in preparation).
2. Lee J, **Krantz MJ**. An aversion to food: marked deglutition syncope (under review NEJM)
3. **Krantz MJ**, Havranek EA, Haynes D, Smith I, Long CS. Effects of inpatient initiation of carvedilol and nurse management in vulnerable heart failure patients: a randomized trial (in preparation)
4. Havranek EA, Estacio RO, Dickinson M, **Krantz MJ**, Steiner J. Effects of electrocardiographic cut-points for left ventricular hypertrophy on mortality: NHANES III (under review Hypertension).
5. **Krantz MJ**, Estacio R, Mehler PS, Baker WA, Long CS. Comprehensive coronary artery disease care: impact of program for vulnerable patients (in preparation).
6. **Krantz MJ**, Havranek E, Haynes D, Smith I, Bucher-Bartelson B, Long CL. Effects of carvedilol on health outcomes in vulnerable heart failure patients. (in preparation).
7. Bartecchi C, Nevin-Woods C, Bucher-Bartelson B, Estacio RO, **Krantz MJ**. Effects of a smoking ordinance on acute myocardial infarction (under review Circulation).
8. Eng MH, Garcia JA, Hangsen A, **Krantz MJ**. Impending Cardiac Rupture (in Press Clin Cardiol).
9. Hiatt WR, **Krantz MJ**. Antiplatelet therapy in peripheral arterial disease and claudication Vascular Medicine 2006;11:1-6.

10. **Krantz MJ**, Rowan S. Paradoxical decrease in blood pressure after relief of cardiac tamponade: the role of sympathetic activity. *Med Sci Monit* 2006;12(2):1-4.
11. **Krantz MJ**, Mehler PS. Heart rate variability in women. *Arch Int Med* 2006;166:247.
12. Schmittner JS, **Krantz MJ**. High-dose methadone and QTc prolongation: strategies to optimize safety. *Journal of Opioid Management* 2006;2(1):49-55.
13. Mehler PS, **Krantz MJ**, Lundgren RA, Estacio RO, MacKenzie TP, Petralia L, Hiatt WR. Bridging the quality gap in diabetic hyperlipidemia: a practice-based intervention. *Am J Med* 2005;118(12):1414.e13-1414.e19.
14. **Krantz MJ**, Coronel S, Hiatt WR. Use of ankle brachial index screening for selecting patients for antiplatelet therapy. *Pharmacotherapy* 2005;25(12):1826-28.
15. Mehler PS, **Krantz MJ**. QT dispersion in anorexia nervosa. *Am J Cardiol* 2005;96(7):1034.
16. Mehler PS, **Krantz MJ**. Bulimia-Medical Complications. *Synapse* 2005;217:42-47.
17. **Krantz MJ**, Coronel SM, Leeman-Castillo, et al. Lipid-modifying therapy in high-risk patients. *Drug Benefit Trends*. 2005;17(suppl E):8-16..
18. **Krantz MJ**, Lowery CM, Martell BA, Gouerevitch MN, Arnsten JH. Effects of methadone on QT interval dispersion. *Pharmacotherapy* 2005;25(11):1523-29.
19. **Krantz MJ**, Haugen SJ, Batal HA, Long CS. Off-site percutaneous intervention reduces hospital length of stay in vulnerable patients with acute myocardial infarction. *Crit Pathways in Cardiol* 2005;4(3):127-130.
20. **Krantz MJ**, Garcia JA. Pseudo-torsade de pointes with underlying wandering atrial pacemaker *Clin Cardiol* 2005;28:355.
21. Hyde JK, **Krantz MJ**, Woods JE. Intracardiac mass in a man infected with human immunodeficiency virus. *Arch Pathol Lab Med* 2005;129(7):943-4.
22. **Krantz MJ**, Zwang O, Rowan S, et al. A cooperative care model: cardiologists and Hospitalists reduce length of stay in a chest pain observation unit. *Crit Pathways in Cardiol* 2005;4:55-58.
23. **Krantz MJ**, Lee D, Donahoo WT, Mehler PS. The paradox of normal serum albumin in anorexia nervosa. *Int J Eat Disord* 2005;37:278-80.
24. Martell BA, Arnsten JH, **Krantz MJ**, Goerevitch MN. Impact of oral methadone on cardiac repolarization and conduction in opioid users *Am J Cardiol* 2005;95(7):915-8.
25. **Krantz MJ**, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. *Pharmacotherapy* 2005;25:611-14.
26. **Krantz MJ**, Estacio RO, Mehler PS. Angiotensin Converting Enzyme Inhibitors and myocardial infarction: a class effect? *Am J Cardiol* 2005;95(7):924.
27. Garcia J, **Krantz MJ**, Baker WA. Two cases of rhythm disturbance. *Consultant* 2005;45(3):327-330.

28. **Krantz MJ**, Garcia JA, Mehler PS. Tramadol-associated pericarditis. *Int J Cardiol* 2005;99:497-8.
29. **Krantz MJ**, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. *J Addict Dis* 2005;24(1):53-60.
30. **Krantz MJ**, Donahoo WT, Melanson EL, Mehler PS. QT interval dispersion and resting metabolic rate in chronic anorexia nervosa. *Int J Eat Disord* 2005;37:166-170.
31. **Krantz MJ**, Lowery CM. Giant Osborn waves in hypothermia *N Engl J Med* 2005;352(2):184.
32. **Krantz MJ**. Angiotensin-Converting Enzyme Inhibitors and stroke: blood pressure reduction is major determinant of risk. *Pharmacotherapy* 2004;24(12):1813-14.
33. Center for Substance Abuse Treatment. Methadone-Associated Mortality: Report of a National Assessment. DHHS Publication No. (SMA) 04-3904. Rockville, MD: Center for Substance Abuse and Mental Health Services Administration, 2004. Available at:www.samhsa.gov
34. **Krantz MJ**, Philip S, Mehler. Angiotensin-Converting inhibitors and diuretics: optimal combination therapy. *Ann Intern Med* 2004;141(11):893.
35. Melanson EL, Donahoo WT, **Krantz MJ**, Poirier P, Mehler PS. Resting and ambulatory heart rate variability in chronic anorexia nervosa. *Am J Cardiol* 2004;94:1217-20.
36. **Krantz MJ**, Mehler PS. Treating Opioid Dependence: Growing Implications for Primary Care. *Arch Int Med* 2004;164:277-88.
37. **Krantz MJ**, Watson K, Leeman-Castillo BA, Mehler PS. Coronary heart disease care in older women: optimizing diagnosis and therapy. *JAMWA* 2004;59:286-294.
38. **Krantz MJ**, Garcia J. Dyslipidemia in high-risk patients. A rational approach to therapy. *Consultant* 2004;44(10):1321-1328.
39. Garcia J, **Krantz MJ**, Baker WA. ECG challenge: Two cases of ST-segment elevation. *Consultant* 2004;44(10):1343-1346.
40. **Krantz MJ**, Lee JK, Spodick DH. Repetitive yawning associated with acute pericardial tamponade. *Am J Cardiol* 2004;94(5):701-2
41. **Krantz MJ**, Mehler PS. Resting tachycardia, a warning sign in anorexia nervosa. *BMC Cardiovasc Disord* 2004;4:10.
42. **Krantz MJ**, Havranek EP, Mehler PS, Haynes DK, Long CS. Impact of a cardiac risk reduction program in vulnerable patients hospitalized with coronary artery disease. *Pharmacotherapy* 2004;24(6):768-775.
43. **Krantz MJ**, Garcia JA. Metabolic disturbances: What the ECG shows. *Consultant* 2004;44(6):803-8.
44. **Krantz MJ**. Cardiovascular effects of ephedra. *JAMA* 2004;291:1560.
45. **Krantz, MJ**. Blood pressure control in type 2 diabetes mellitus. *Ann Intern Med* 2004;140:487.

46. **Krantz MJ**, Mehler PS. Methadone and QT-prolongation: a dose-dependent effect? *Am J Cardiol* 2004;93:952.
47. **Krantz MJ**, Mehler PS. Synthetic Opioids and QT Prolongation. *Arch Intern Med* 2003;163:1615.
48. **Krantz MJ**. Angiotensin Converting Enzyme Inhibitors: Optimal management of cardiovascular risk. *Am J Cardiol* 2003;92(7):900.
49. Leavitt S, **Krantz MJ**. Cardiac considerations in methadone maintenance treatment (MMT). Special Report. *AT Forum* 2003. Available at: www.atforum.com.
50. **Krantz MJ**, Martell B, Arnsten JH, Goerevitch MN. Medications that prolong the QT interval. *JAMA* 2003;290(8):1025.
51. **Krantz MJ**, Baker WA. Non-invasive evaluation of ischemic heart disease. *Consultant* 2003;43(1):23-32.
52. **Krantz MJ**, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. *Pharmacotherapy* 2003;23(6):802-805.
53. Mehler PS, **Krantz MJ**. Anorexia nervosa Medical issues. *J Women's Health* 2003;12(4):331-340.
54. **Krantz MJ**, Mehler PS. Case in point: Cardiac complications in anorexia nervosa. *Consultant* 2003;43(9):1095-7.
55. **Krantz MJ**. Secondary prevention of coronary artery disease: Combining the evidence. *Primary Care Case Reviews* 2003;6(3):110-20.
56. Baker WA, **Krantz MJ**. Aortic Stenosis in the adult. *Primary Care Case Reviews* 2003;6(4):162-9.
57. **Krantz MJ**, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very high-dose methadone. *Ann Intern Med*. 2002;137:501-4.
58. Leavitt S, **Krantz MJ**, Ling W, Payte TJ, Tenore PL, Stimmel B, Casodonte PP, Kipnis S, Vossi F. Expert Panel Clinical Guidelines on LAAM In Opioid Agonist Therapy (OAT). Technical Assistance Publication (TAP) Series. U.S. Department of Health and Human Services. Rockville, MD 20857, 2002.
59. **Krantz MJ**, Dart RC, Mehler PS. Transient pulmonary infiltrates possibly induced by quinine sulfate. *Pharmacotherapy* 2002;22:775-8.
60. **Krantz MJ**. A practical approach to cardiac stress testing. *Primary care case reviews* 2002;5:26-33.
64. **Krantz MJ**, Baker WA. ECG challenge. *Consultant* 2002;42:501-516.
62. **Krantz MJ**, Llewellyn A, Moreo K. Reducing vascular events in patients with diabetes. *Case Management Society of America, CMSA*, 2002. Available at: www.cmsa.org.
63. **Krantz MJ**, Baker WA. ECG challenge: Test your interpretative skills. *Consultant* 2002;42:1757-68.

64. **Krantz MJ**, Woods JA, Havranek EP, Linas S. Simultaneous Malignant hypertension and Cardiac Tamponade. *Am J Kidney Dis* 2002;39:E17, 1-5.
65. **Krantz MJ**, Llewellyn A, Moreo K. Case Management resource path for reducing vascular events in patients with diabetes. Case Management Society of America, CMSA, 2002. Available at: www.cmsa.org
66. **Krantz, MJ**. Clinical Concepts: Cardiovascular Health in MMT Patients, *AT Forum* 2001;10(4):1-5.
67. **Krantz, MJ**, Baker WA, Long CS. Secondary MI Prevention: Which drugs are essential? *Consultant* 2001;41:1377-1385
68. Colizzo F, Hastie AT, **Krantz MJ**. Investigation of respiratory epithelial surface and ciliary axoneme protein changes after formaldehyde exposure. *J Toxic Environ Health* 1992;35:221-34.
69. Hastie AT, Colizzo F, Evans L, **Krantz MJ**, Fish J. Initial characterization of tektins in cilia of respiratory epithelial cells. *Chest* 1992;101: 47S-48S.
70. Hastie AT, **Krantz MJ**, Colizo F. Identification of surface components of mammalian respiratory cilia. *Cell Motility and the Cytoskeleton* 1990;17: 317-28.

Funded Research

1. Principal Investigator, Colorado Prevention Center, CCPD grant on Global CV risk assessment; 3 year \$1.6 million.
2. Chairman, data safety and monitoring board: ActiveBiotics Inc. Protocol ABI-1648-022PROVIDENCE-1. Prospective randomized double blind study of rifalazil treatment on the number of vascular interventions and peripheral vascular disease endpoints in Chlamydia pneumonia seropositive patients.
3. Chairman, data safety and monitoring board: Angec Inc., Protocol AG-IHD-0101 IND#11570. Phase I Protocol. An open label dose escalation study to assess the safety of AMG0001 administered via intramyocardial injection in patients with ischemic heart disease not amenable to percutaneous coronary intervention.
4. Principal Investigator: Glaxo SmithKline Inc., Protocol SKF#105517/379, "Effects of inpatient initiation of the beta blocker Carvedilol on Health Outcomes in vulnerable heart failure patients: The ECHO trial. Start date Sept 2002, projected completion date Sept 2005.
5. Co-investigator: Partnership Program to Reduce Cardiovascular Disparities. Funded at \$6 million as NHLBI RFA HL-04-002 through 2010.
6. Co-investigator: Genetic-Adrenergic Interactions in Myocardial Failure. Principal Investigator: Michael Bristow. 3R01 HL48013.
7. Principal investigator: Pfizer Global research: atorvastatin and torcetrapib phase IV.
8. Co-investigator: Safety and efficacy of KW-3902, a selective adenosine A1 receptor antagonist for use in decompensated heart failure. Protocol CKI-201, NovaCardia.
9. Sub-investigator: The WARCEF trial: Warfarin versus aspirin in reduced cardiac ejection fraction. National Institute of Neurological Disorders and Stroke (NINDS).

10. Sub-investigator: CV Therapeutics Protocol CVT 5131. "Phase III randomized double-blind study of intravenous CVT-3146 vs. Adenoscan® in patients undergoing stress myocardial perfusion imaging."
11. Co-investigator: Effects of gender on autonomic nervous system and baroreflex control of blood pressure and vascular adrenergic responsiveness. University of Colorado General Clinical Research Center Protocol #1305.
12. Principal investigator: Treatment Seeking Behavior for Symptoms of Acute Myocardial Infarction among Latina and non-Latina women, AHA Pre-doctoral fellowship Grant, Bonnie Leeman-Castillo.
13. Sub-investigator: Biogen, Inc., Protocol C-1701, "A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Multiple Oral Dose Administration of BG9928 in Stable Heart Failure Patients"
14. Sub-investigator: Proctor & Gamble, Protocol 1999053, "Complement Inhibition in Myocardial Infarction Treated with Percutaneous Transluminal Coronary Angioplasty"
15. Sub-investigator: Orion Pharma Inc., Protocol 3001069, "Randomized Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure." The REVIVE study.
16. Sub-investigator: Organon Inc., Protocol 6470. The AMADEUS trial: a once weekly direct thrombin inhibition, idraparinix vs. adjusted dose warfarin in atrial fibrillation.
17. Sub-investigator: PREMIER national registry of myocardial infarction.